Bristol-Myers' Opdivo+Yervoy HCC study yields 31% ORR
Bristol-Myers announced first results from the Opdivo plus Yervoy cohort of the Phase 1/2 CheckMate -040 study, evaluating the Immuno-Oncology combination in patients with advanced hepatocellular carcinoma, or HCC, previously treated with sorafenib. With a minimum follow-up of 28 months, the blinded independent central review objective response rate, or ORR, was 31% per Response Evaluation Criteria in Solid Tumors version 1.1. At the time of data cutoff, the median duration of response was 17.5 months. These data will be featured at the ASCO Annual Meeting 2019 in Chicago in a poster display on Monday, June 3. Patient responses were achieved regardless of baseline tumor PD-L1 status. Opdivo plus Yervoy showed an acceptable safety profile and the addition of Yervoy yielded no new safety signals in any treatment arm.